Lisvy®
Alternative Name: FC-Patch Low; Gestodene (GES) + ethinyl estradiol (EE) Patch
Description: One patch applied once per week for three weeks (21 days) followed by one week without patch per cycle. Each patch contains 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene.
Product Details
User: Female
Hormonal: Yes
Delivery Method: Transdermal
Duration Type: Short-acting
Duration: One week
Regimen: - weekly (3 weeks on, 1 week without patch)
- weekly (3 weeks on, 1 week without patch)
Dose: 0.02mg EE and 0.05mg gestodene per day
Active Pharmaceutical Ingredient (API): - ethinyl estradiol
- gestodene
- ethinyl estradiol
- gestodene
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: WHO HRP, Bayer HealthCare, Gedeon Richter Plc.
Project Phase: Limited Market Availability
Development Stage: SRA/WHO PQ Approved
Active Development: Yes
Status Details: - This patch was approved in the EU in 2014 and was outlicensed by Bayer to Gedeon Richter, a Hungarian Pharma company. Market entry occurred in late 2015, under the name Lisvy®.
- Product was withdrawn in October 2016 over concerns about the results of a stability test run by Bayer.
- This patch was approved in the EU in 2014 and was outlicensed by Bayer to Gedeon Richter, a Hungarian Pharma company. Market entry occurred in late 2015, under the name Lisvy®.
- Product was withdrawn in October 2016 over concerns about the results of a stability test run by Bayer.
Additional Information
References: Gedeon Richter Plc. website: http://www.richter.hu/en-US/investors/announcements/Pages/extraord150127...
Gedeon Richter Plc. website: http://www.richter.hu/en-US/investors/announcements/Pages/extraord150127...